DHODH inhibition is curative in a genetically engineered mouse model of T-ALL. (A) Schema outline of the experiment, with dosing and treatment time points. (B) Peripheral WBC counts measured in mice with T-ALL that either received no treatment (untreated) or treatment with BRQ 50 mg/kg every 3 days (brequinar). Each group included 3 animals. Measurements were recorded after 1, 2, or 3 doses of BRQ, with matched untreated controls. (C) Spleen weights measured untreated or brequinar mice. Each group included 3 animals. Measurements were recorded after 1, 2, or 3 doses of BRQ, with matched untreated controls. (D) Kaplan-Meier survival curve comparing untreated brequinar mice. n = 17 in the untreated group; n = 9 in the brequinar group; P < .0001. (E) Disease burden in the bone marrow as measured by the percentage of GFP⁺ murine CD45⁺ cells detected by flow cytometry after 5 doses of BRQ. Each group included 3 animals. (F) WBC counts, hemoglobin, and platelet counts from both wild-type (n = 9) and BRQ-treated mice (n = 9). GEMM, genetically engineered mouse model; RO, retroorbital. Created with BioRender.com.